Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals
Table 4
The clinical characteristics of the overweight/obese subjects.
ADRB3 rs4994 genotype
T/T ()
T/C ()
C/C ()
value
Male/female
114/58
74/28
8/3
0.56†
Age (years)
65 (29–88)
66 (31–83)
68 (51–80)
0.70
BMI (kg/m2)
25.0 (23.0–34.7)
24.7 (23.0–37.2)
25.0 (23.0–35.8)
0.63
Obesity (%)
4.1
2.0
27.3
<0.01†
Alcohol intake (%)
47.1
52.0
54.5
0.52†
Ever smoking (%)
40.7
45.1
54.5
0.56†
Systolic BP (mmHg)
121 (90–171)
120 (93–170)
121 (99–142)
0.81
Diastolic BP (mmHg)
74 (48–96)
75 (50–102)
71 (59–91)
0.25
LDL_C (mg/dL)
122 (61–199)
127 (76–191)
130 (108–169)
0.63
HDL_C (mg/dL)
57 (34–103)
59 (30–117)
62 (42–84)
0.90
Triglyceride (mg/dL)
104 (46–508)
110 (43–431)
122 (56–210)
0.36
AST (IU/L)
23 (14–67)
23 (13–65)
22 (18–83)
0.90
ALT (IU/L)
22 (7–91)
21 (10–74)
25 (15–168)
0.88
GGT (IU/L)
27 (10–180)
29 (6–163)
33 (20–116)
0.55
HbA1c (%)
5.4 (4.9–9.8)
5.4 (4.9–8.7)
5.2 (5.0–5.8)
0.45
Fasting plasma glucose (mg/dL)
98 (68–244)
96 (78–201)
98 (88–114)
0.82
Fasting serum insulin (μU/mL)
5.6 (1.2–31.5)
5.2 (1.5–22.3)
6.7 (3.2–38.6)
0.43
HOMA-IR
1.4 (0.3–8.3)
1.2 (0.3–6.4)
1.6 (0.8–10.9)
0.45
Hypertension (%)
46.5
44.1
54.5
0.77†
Diabetes (%)
18.0
13.7
18.2
0.64†
Dyslipidemia (%)
65.1
70.6
63.6
0.65†
NAFLD (%)
33.1
36.3
63.6
0.12†
Data are the median (range) or proportion for categorical variables. ADRB3: beta-3-adrenergic receptor; BMI: body mass index; BP: blood pressure; LDL_C: low-density lipoprotein cholesterol; HDL_C: high-density lipoprotein cholesterol; AST: aspartate transaminase; ALT: alanine transaminase; GGT: γ-glutamyltransferase; HbA1c: hemoglobin A1c; HOMA-IR: homeostasis model assessment for insulin resistance; NAFLD: nonalcoholic fatty liver disease. Calculated among 170 subjects for whom information could be collected. Calculated among 267 subjects for whom information could be collected. †Analyzed by Fisher’s exact test, otherwise Kruskal Wallis test.
